Accessibility Menu
Mustang Bio logo

Mustang Bio(NASDAQ) MBIO

Market Cap$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-64%
1 Month-16%
$0.61
+5.29%
+0.03Today
Mustang Bio last closing stock price
MetricPriceDate
Last closeUSD 0.592026-08-10
Mustang Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.34%USD 0.582026-08-03
1 month-16.13%USD 0.702026-07-10
3 month-10.35%USD 0.662026-05-12
Year to date-39.85%USD 0.982025-12-31
1 year-64.45%USD 1.662025-08-08
3 year-99.74%USD 226.502023-08-11
5 year-99.97%USD 2,107.502021-08-11
Since inception-99.99%USD 7,350.002017-08-22

Mustang Bio Financials at a Glance

Market Cap

$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.03M

EPS (TTM)

-$0.45

P/E Ratio

-1.34

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$0.61

Volume

30,997.362

Open

$0.60

Previous Close

$0.59

Daily Range

$0.56 - $0.62

52-Week Range

$0.53 - $1.88

Estimated Earnings Date

Aug 18, 2026

MBIO News

Scientists looking through microscopes - Copy

Why Mustang Bio Stock Galloped Higher Today

Keith SpeightsMay 18, 2021
Happy businessman

Why Mustang Bio Stock Is On Fire Today

George Budwell, PhDApr 18, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mustang Bio

Mustang Bio develops therapies for rare genetic diseases and hard-to-treat cancers. Its treatments aim to help patients with limited medical options. The company focuses on gene and cell therapies that target specific health problems.

Lab Coats & Life Savers: Mustang’s Main Offerings

  • Gene Therapy Programs: Treatments for rare genetic disorders, such as immune system deficiencies. (0% of revenue; pre-commercial)
  • CAR T Cell Therapies: Engineered immune cells designed to attack blood cancers and solid tumors. (0% of revenue; pre-commercial)
  • Oncolytic Virus Therapies: Modified viruses that target and destroy cancer cells in the brain. (0% of revenue; pre-commercial)
  • Combination Therapies: Integrates cell therapy and virus therapy for aggressive brain cancers. (0% of revenue; pre-commercial)
  • Research Partnerships: Collaborations with hospitals and universities to access new technologies. (0% of revenue; pre-commercial)

Growth Spurts & Strategic Moves

  • Formed exclusive research partnerships with City of Hope and Nationwide Children’s Hospital (2015–2025).
  • Sold cell processing equipment to AbbVie in February 2025 to raise cash.
  • Raised $14.5 million through equity offerings and warrant exercises in 2025.
  • Terminated Worcester facility lease and reduced operating costs in 2025.

What Makes Mustang Bio Stand Out

Mustang Bio focuses on rare diseases and cancers with few treatment options. It partners with leading research centers to access new therapies. The company combines cell and virus therapies to tackle complex tumors.

Five Things You Need to Know

  • No revenue generated from 2023 to 2025; all programs are pre-commercial.
  • Net loss improved to $1.9 million in 2025, down 88% from 2024.
  • Cash and cash equivalents were $17.3 million at December 31, 2025.
  • Full-time headcount is 4 employees as of December 31, 2025.
  • Raised $14.5 million in 2025 through equity and warrant sales.

Bottom Line

Mustang Bio has shifted from heavy spending to cost control and cash preservation. The company remains focused on developing advanced therapies for rare and difficult diseases.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Manuel Litchman, MD

Website

www.mustangbio.com

Headquarters

Waltham, MA 02453, US

MBIO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-34.23%

Return on Capital

-25.52%

Return on Assets

-19.43%

Earnings Yield

-74.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.58M

Volume

31.00K

Avg. Volume

131.10K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.52M

EBITDA

-$3.03M

Operating Cash Flow

-$4.55M

Capital Expenditure

$0.00

Free Cash Flow

-$4.55M

Cash & ST Invst.

$15.15M

Total Debt

$0.00

Mustang Bio Performance Analysis

Mustang Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Mustang Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Mustang Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -562.14-0.8%
20232023-12-31USD -299.87-46.7%
20242024-12-31USD -25.84-91.4%
20252025-12-31USD -0.39-98.5%
Mustang Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3042.3%
Q42025-12-311.7%
Q12026-03-31-90.0%
Q22026-06-30-14.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.14M

N/A

Employees

4

N/A

Net Income

-$1.07M

-40.7%

EBITDA

-$1.07M

-40.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$15.15M

+19.7%

Total Debt

$0.00

N/A

Accounts Receivable

$217.00K

+0.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-19.43%

N/A

Return on Invested Capital

-45.77%

N/A

Free Cash Flow

-$1.01M

+24.6%

Operating Cash Flow

-$1.01M

+24.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRAWTraws Pharma, Inc.
$0.54+1.50%
RNAZTransCode Therapeutics, Inc.
$3.88-2.02%
EVGNEvogene Ltd.
$0.63+5.37%
DWTXDogwood Therapeutics, Inc.
$1.83+1.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About MBIO

What is the current price of Mustang Bio?

Mustang Bio is trading at $0.59 per share.

What is the 52-week range for Mustang Bio?

Over the past 52 weeks, Mustang Bio has traded between $0.53 and $1.88.

How much debt does Mustang Bio have?

As of the most recent reporting period, Mustang Bio reported total debt of $0.00.

How much cash does Mustang Bio have on hand?

Mustang Bio reported $15.15M in cash and cash equivalents in its most recent financial results.

What is Mustang Bio’s dividend yield?

Mustang Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services